INTRODUCTION
The cytolytic activity that "sensitized" lymphocytes exhibit towards alloantigen-bearing target cells in vitro is widely considered to be of importance in vivo, particularly in allograft rejection (1, 2) . Recent evidence strongly suggests that the effector cells in such cytolytic phenomena are predominantly, if not exclusively, thymus-derived (T) lymphocytes (3, 4) . Our previous studies (5) (6) (7) (8) have indicated that among reversible inhibitors of T-cell mediated cytolysis in vitro are those agents which stimulate lymphocyte cyclic 3',5'-adenosine monophosphate (cAMP)1 accumulation. The overall efficacy of these agents in inhibiting cytolysis appears related to the length of time over which they cause elevation of cAMP (5) . Thus, isoproterenol was found to augment lymphocyte cAMP levels only temporarily (< 1 h) and was an inefficient inhibitor of cvtolvsis in long-term (> 4 h) cultures (5) . The prostaglandins E1 and E2 on the other hand, raised lymphocyte cANIP levels for periods in excess of 4 h and strongly inhibited in vitro cytolysis for similar periods (5, 7). We have recently had occasion to study the effects of another adenylate cyclase-stimulating agent, cholera enterotoxin (8) . This agent was found to cause a slow but extremely protracted ( > 24 h) elevation of lymphocyte cAMIP levels in vitro, and at concentrations of 1 ng/ml, effectively! suppressed lymphocyte-mediated cytolysis without affecting cell viability (8, 9) . These findings suggested to us that cholera toxin might effectively suppress lymphocyte-mediated cytolysis in vivo and thus afford a pharmacologic means of control of an efferent arm of the immune response. Such studies are the subject of this communication.
METHODS
Lymphocyte-mediated cytolysis. The procedure employed has previously been described in detail (10, 11) . A murine mastocytoma cell line (P815 of the DBA/2 strain) was used both as immunizing alloantigen and as a target cell in cytolytic assays. The mastocytoma was serially passaged in ascitic fluid through adult DBA/2 female mice. For immunization, the cells were aspirated into Eagle's medium (MEM) (Microbiological Associates, Inc., Bethesda, Md.) containing 200 IU heparin/ml, washed twice in Tris buffer (10) , and 107 cells given intraperitoneally (i.p. Spleen cells obtained 10 days after immunization and target cells were incubated together in a reaction volume of 1 ml MEM containing 10% heat-inactivated fetal calf serum. These cell mixtures were incubated for 6 h at 370C in an atmosphere of 10% C02, 90% air. Routinely, 10' "Cr target cells and 107 lymphocytes were used. When fewer lymphocytes from immune animals were assayed, the total lymphocyte concentration was adjusted to 107/ml by the addition of normal syngeneic C57BL/6 spleen cells.
At the end of incubation the cells were spun down (1,000 rpm for 5 min), an aliquot of cell-free supernate taken, and its 51Cr content measured in a -y-spectrometer (Nuclear-Chicago Corp., Des Plaines, Ill.). The percentage of the 51Cr which was released into the supernate on incubation was equated with the percentage of target cell lysis (10, 11) . The percentage of specific cytolysis was evaluated by subtracting from the lysis obtained with immune C57BL/6 lymphocytes that amount of 5lCr released in the presence of the same number of normal C57BL/6 spleen cells (11) .
Agglutinating antibody. Sera obtained from C57BL/6 mice, at various times after sensitization, were assayed for agglutinating antibody activity against DBA/2 alloantigens by the method of Stimpfling (12) . The DBA/2 mastocytoma cell was employed as the target cell and polyvinylpyrrolidone was used as an agglutination-augmenting agent. All sera were decomplemented (560C, 40 min) before use. The maximal serum dilution causing agglutination was recorded.
cAMP measurements. The method of Brown, Albano, Ekins, and Sgherzi was used (13) , employing a modified extration procedure (8) . The application of this assay to lymphoid cell suspensions has previously been described in detail (5, 8 , and has previously been described in detail (14) . Assay for antibody production against cholera enterotoxin. The method used has previously been described in detail (8) . Human peripheral leukocytes from donors sensitive to ragweed were incubated with 2.5 ng/ml of cholera enterotoxin and with various dilutions of mouse serum, obtained on different occasions after cholera toxin immunization. After 60 min incubation, antigen E was added and histamine release from the leukocytes measured (8) . Cholera toxin markedly inhibited histamine release in this system, an inhibition that was specifically reversed by anticholera toxin antibody. The inhibition of histamine release by cholera toxin has been significantly reversed by 1: 104 dilutions of dog antitoxin antiserum (8) . None of the mouse sera employed, even at final dilutions of 1/10, reversed the cholera toxin effect.
RESULTS
Adult C57BL/6 mice were given 107 DBA/2 mastocytoma cells (P815) i.p. Cholera enterotoxin (l 'tg) was administered i.p. on the day of antigenic challenge, or on days 4, 7, or 10 thereafter. Pooled spleen-cell suspensions were made from each group (six mice/group) 11 days after alloantigenic stimulation, and the cytolytic activity of these populations towards TMCr-labeled DBA/2 mastocytoma cells was assessed (10, 11) . Typical results are shown in Fig. 1 A. Cholera enterotoxin administration at the time of immunization with DBA/2 mastocytoma cells had no effect on the subsequent de (8) . To study whether there was a correlation in vivo between these immunosuppressive effects and cellular cAMP levels, the following experiment was devised. Adult C57BL/6 mice were given 107 DBA/2 mastocvtoma cells i.p. One-half of these mice (30 animals) were given 1 tig cholera enterotoxin i.p. At daily intervals thereafter spleens were removed from both normal animals and those receiving choleragen, and the cAMIP content of both groups individually measured (8, 13) . Additionally, normal C57BL/6 spleen-cell suspensions were cultured for varying periods of time in vitro in the presence of cholera enterotoxin and subsequently were assayed for cAMP content. As can be seen (Fig. 2) , cAMP levels in vitro and in vivo were elevated for prolonged periods by cholera enterotoxin treatment. These levels fell to base-line values, however, by 30-36 h in vitro and by 72 h in vivo. The data presented here thus demonstrates immune suppression which follows, by a considerable period, transitory elevation of cAMP levels.
DISCUSSION
These studies demonstrate that cholera enterotoxin administered in vivo can cause a profound suppression of the immune response both to allogeneic cell suspensions and to skin allografts. The mechanism of such suppression is unclear. Our working hypothesis based on previous experiments (5, 8) has been that increased cAMP levels caused by adenylate cyclase stimulation inhibits The values shown are means of triplicate assays ±+SEM.
the synthesis and/or release of soluble mediators required for the lytic activity of T lymphocytes. The present in vivo studies show, however, a suppression of cytolytically active effector cells at a time considerably later than the observed increased cAMP levels after cholera toxin administration. The suppression of cytolytic activity by cholera toxin treatment on day 10, a time when many cytolytically ac- (11) , would seem to be a direct analogy of events previously observed in vitro and related to the elevated cAMP levels in the effector cell population (5, 8) . Suppression by administration of choleragen on day 4, however, may be due to inhibition of antigen-induced clonal proliferation, for several investigations have recently shown that mitogen induced lymphocyte transformation is inhibited by agents that elevate cAMP levels (16, 17) . Alternatively, or additionally, it may be that increased cAMP levels 4 and 5 days after antigenic stimulation, a time of rapid cellular proliferation, causes lysis of newly differentiated cells, a phenomenon recently described with cultured lymphoma cells by Daniel, Litwack, and Tompkins (18) .
We suggest that the decrease in serum antibody titers observed in cholera toxin-treated animals could be due to diminished capacity of plasma cells to secrete antibody. Evidence that this can occur has recently been provided by the observation that adenylate cyclase stimulation of plasma cells in vitro leads to a fall in splenic plaqueforming cell numbers against sheep erythrocytes.3
The relatively long half-life of mouse immunoglobulin (19) would be compatible with the observation that treatment of animals with cholera toxin on day 10 had no effect on serum antibody titers measured 24 h later.
Although cholera toxin treatment markedly suppressed the development of antibody formation and cytolytically active lymphocytes against skin allografts, interference with the time of onset of skin graft rejection was only rarely observed. One assumes that this relates to the small number of effector cells required for skin rejection; 3Melmon, K., J. Weinstein, and H, R. Bourne. 1973.
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a number presumably beyond the limits of detection of the cytolvtic assay system employed. Although unlikely, it is of course conceivable that the cells responsihle for in vitro cytolytic activity play no major role in allograft rejection. Alternatively, it may be that the toxin stimulates a process necessary for allograft rejection and that this compensates for the relative disappearance of cytolytically active cells.
It is of interest to note that cholera toxin administration on day 0 had no effect on the immune response to allogeneic cell suspensions (Fig. 1A) , but markedly suppressed the response to skin allograft (Table I) . This finding may be related to the nature of the antigenic stimulus and the timing of the host's proliferative response.
In anly event, it appears that significant ininiutnosuippression in vivo can be induced by an agent that causes increased levels of cAMP. The optimum dose and time of administration of cholera toxin and its possible synergy with other immunosuppressive regimens needs further evaluation, as does the mechanism by which transient increases in cAMP levels can apparently obviate an immune response 7-10 days later. Nonetheless, the present results suggest that such agents afford a novel means of immunosuppression, and imply a favorable prognosis for the pharmacologic control of the immune response.
